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Abstract
It is widely assumed that genotoxin-induced damage (e.g., G-to-T transversions) to the tumor
suppressor gene, p53, is a direct cause of cancer. However, genotoxins also induce the stress
response, which upregulates p53 transcription and the formation of secondary structures from
ssDNA. Since unpaired bases are thermodynamically unstable and intrinsically mutable, increased
transcription could be the cause of hypermutation, and thus cancer. Support for this hypothesis has
been obtained by analyzing 6662 mutations in all types of cancer compared to lung and colon
cancers, using the p53 mutation database. The data suggest that genotoxins have two independent
effects: first, they induce p53 transcription, which increases the number of mutable bases that
determine the incidence of cancer. Second, genotoxins may alter the fate, or ultimate mutation of
a mutable base, for example, by causing more of the available mutable Gs to mutate to T, leaving
fewer to mutate to A. Such effects on the fate of mutable bases have no impact on the incidence
of cancer, as both types of mutations lead to cancer.
Background
Base damage to p53
The wild-type p53 protein inhibits neoplastic transforma-
tions as well as tumor growth. Moreover, if DNA damage
occurs, p53 is induced and maintains the integrity of the
genome by causing cell cycle arrest, to allow for repairs or,
in the event of severe damage, by sacrificing the damaged
cells (apoptosis). More than half of all cancers are associ-
ated with mutations in the p53 gene [1-3], and the vast
majority of these occur in the sequence-specific DNA
binding domain. DNA strand breakage and genetic insta-
bility are generally thought to arise as a result of direct
base damage by genotoxic stressors, such as reactive oxy-
gen species, which are not only in the environment but are
formed in vivo under normal physiological conditions. An
extensive literature documents the effect of genotoxins
directly on the p53 gene [4,5]. Of particular importance in
the present context are genotoxin-induced G:C-to-T:A
transversions that occur at high frequencies in some can-
cers [6-8]. While these transversions are relatively rare in
most mutable genes, they represent a "signature" p53
mutation in experiments which document DNA damage
by carcinogens. These studies appear to implicate base
damage as the direct cause of p53 mutations, and to sug-
gest that such damage increases the incidence of lung can-
cer.
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However, severe base damage results in apoptosis in vivo,
and is unlikely to foster the creation of robust cancer cells.
A more conducive environment for the development of
cancer may emerge from a response to relatively mild
DNA damage that activates stress response mechanisms
[9] and upregulates p53 transcription. Transcription drives
secondary structures which expose unpaired bases for
hypermutation at specific sites ("hot spots"). Mutations in
p53 inactivate the protein, which regulates interactions
including the coordination of DNA repair with the rate of
cell growth. These relationships will be specifically dis-
rupted without significant damage to metabolism in gen-
eral, providing ideal conditions for the creation and
selection of cells with high rates of cell division, thus lead-
ing to tumorigenesis. This "directed" mutagenic mecha-
nism, dependent upon the stress response rather than
random base damage, is more likely to be responsible for
the evolution of hypermutable bases in critical regulatory
genes such as p53.
The stress response
A number of investigations in the microbial world have
provided evidence that environmental stressors derepress
and/or activate transcription specifically in genes that
must mutate to overcome the stress [10,11]. The implica-
tions of this mutagenic mechanism for evolution are pro-
found [12,13]. The increased rate of stress-induced
transcription based on mRNA accumulation and half-life
has been correlated with mutation rates, and predicted
effects of promoter strength and supercoiling on mutation
frequencies have been demonstrated in prokaryotes
[10,14,15]. In higher organisms, only a few studies sup-
porting this mechanism are available [16,17]; also, con-
vincing evidence exists for a direct dependence of
mutation frequency on the rate of transcription during
somatic hypermutation in the immune response [18].
Genotoxic stressors cause strong promoter activation and
upregulation of p53 transcription, which could increase
p53 mutation frequencies. The persistent over-expression
of p53 protein is commonly associated with the accumu-
lation of p53 mutations and tumorigenesis [19,20]. The
cellular stress response involves a large number of genes
in a complex network, and genotoxins induce transcrip-
tional upregulation of p53  by both indirect and direct
means. DNA-damaging genotoxins elicit a strong p53 pro-
tein-dependent response resulting in upregulation of p53
transcription [9]. This activation of transcription occurs
either by direct interaction with the basal p53 promoter
[21] or by indirect upregulation, which typically involves
activation by the ubiquitous transcription factor, NF-κB.
Specifically, benzo [a]pyrene, a potent genotoxic compo-
nent of cigarette smoke, upregulates p53 transcription via
induction of NF-κB [22]. As the p53 gene is responsive to
many stress-related signals [23,24], its expression is upreg-
ulated by a variety of genotoxic stressors. The activation of
p53  transcription will drive supercoiling, which creates
and stabilizes ssDNA secondary structures containing
unpaired bases that are intrinsically mutable [25,26].
Therefore transcription, per se, could promote hypermuta-
tion and ultimately, cancer.
Intrinsically mutable bases
Unpaired bases of ssDNA are thermodynamically unsta-
ble, and point mutations occur by known chemical mech-
anisms having finite, significant activation energies under
physiological conditions. For example, the hydrolytic
deamination of cytosine in ssDNA occurs 160 times more
frequently than in dsDNA, and CpG sequences are meth-
ylated non-enzymatically by S-adenosylmethionine, ren-
dering them 40 times more susceptible to deamination
than non-methylated sequences [26]. In the p53  gene,
most of the hypermutable bases are methylated CpGs.
Two major non-enzymatic mutagenic events, the hydro-
lytic deamination of cytosine and the oxidation of gua-
nine, are estimated to occur 100–500 times per day in
each human cell, and 2000–10000 purine bases turn over
per day in each cell due to hydrolytic depurination and
repair. Thus, G and C are much more mutable by these
mechanisms than A and T, and, because of its size, A is
more likely than C or T to replace G at apurinic sites
[26,27]. In human genetic disease, 35% of single base
mutations are in CpG dinucleotides and over 90% are C-
to-T or G-to-A mutations occurring at a frequency 42-fold
higher than that predicted by chance [28]. Thus, these are
the primary "default" or background mutations in ssDNA
that are determined by the inherent chemical instability of
each base and the extent to which it is exposed during
events such as replication and transcription.
Transcription-induced intrinsic mutagenesis, due only to
the extent to which a base is unpaired in ssDNA, correlates
with mutation frequencies in p53 [17]. Interestingly, this
circumstance would be difficult to distinguish from one
that is also dependent upon, and therefore superimposed
upon base exposure; for example, genotoxin-induced G-
to-T transversions, and enzyme-catalyzed mutations, both
of which are more effective on ssDNA than dsDNA.
Predicting base mutability in vivo
In previous studies a computer algorithm (mfg) has been
used to simulate the formation of secondary structures in
ssDNA during transcription and predict the relative muta-
bility of unpaired bases in these structures [11]. This pro-
gram performs a sliding window analysis of any given
sequence, in which a chosen length of nucleotides is
folded successively, beginning with each base in the
sequence. Mfg interfaces with another computer program
(mfold) that reports all possible secondary structures that
can form from each folded segment, in order of their sta-Cancer Cell International 2006, 6:27 http://www.cancerci.com/content/6/1/27
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bility. The mfg program predicts (i.e., calculates) the muta-
bility of each unpaired base from two key variables: a) the
stability of the most stable secondary structure in which
the base is unpaired, and b) the percent of total folds in
which it is unpaired. The Mutability Index (MI) is the
product of these two factors: the stability (-ΔG) of the
most stable SLS multiplied by percent unpaired.
The computer algorithm, mfg, has been used to analyze
hypermutable codons in p53 [17]. Using the non-tran-
scribed strand, twelve hypermutable bases (the first two
positions of codons 175, 245, 248, 249, 273, and 282)
were analyzed (a total of 3492 mutations), and the com-
puter-predicted MIs were found to correlate (r2 = 0.77; p =
0.0002) with the mutation frequencies. No correlation
was found using the transcribed strand (r2 = 0.27; p = 0.1).
To determine the relative contribution of percent
unpaired and -ΔG to MI, all three are plotted independ-
ently against mutation frequency (Fig. 1). Secondary
structure stability shows no correlation with mutation fre-
quency (Fig. 1c) while the correlation with percent
unpaired (Fig. 1b) is comparable to that of MI (Fig. 1a).
Therefore, the extent to which a base is unpaired during
transcription is a much better predictor of base mutability
(in p53) than the stability of the most stable structure in
which it is unpaired. Another variable that can be ana-
lyzed by this program is the effect of transcription level,
which correlates with the amount of RNA transcript and
ssDNA formed [29,30]. Over a broad range of transcrip-
tion levels (> 40 nt window size) predicted mutation fre-
quencies increase incrementally, suggesting a threshold
mechanism for inducing the level of transcription in p53
that leads to mutagenesis.
As the implications of the previous analyses are not yet
widely recognized, an original analysis of the p53 muta-
tion database is presented here. These data provide strong
support regarding the roles of genotoxins, base damage,
and transcription with respect to the incidence of cancer.
Thus, new lines of evidence support the conclusion that
genotoxins: (1) activate p53 transcription and hypermuta-
tion, which increases the number of mutable bases and
thus the incidence of cancer, and (2) alter the fate of muta-
ble bases, which does not affect the incidence of cancer.
Results and discussion
A systems analysis of 6662 mutations in the International
Agency for Research on Cancer TP53 Mutation Database
(version R4) [31,32] has revealed relationships and mech-
anisms not easily examined in the laboratory. Due to the
rarity of mutations, a large database is essential for obtain-
ing reliable values in assessing the origin and fate of muta-
ble bases in cancers. Moreover, these mutations occurred
under physiological conditions, whereas experimental
conditions for analyzing effects of genotoxins in vitro may
not reflect conditions in vivo. In our analyses, the dual role
of genotoxins was discovered only in light of two kinds of
information extracted from the same large p53 mutation
database: first, genotoxins induce a stress response that
upregulates p53 transcription and mutation frequency to
a comparable extent in lung cancer as in all types of can-
cer; this frequency determines the incidence of cancer.
Second, base damage by genotoxins increase the G-to-T
Linear regression analyses of the correlations between predicted and observed mutation frequency in p53 Figure 1
Linear regression analyses of the correlations between predicted and observed mutation frequency in p53. The mutations ana-
lyzed are the first two positions of codons 175, 245, 248, 249, 273, and 282. Mutation frequencies are correlated with: (a) MI, 
the base mutability index; (b) Percent unpaired, the fraction of total folds during transcription in which each mutable base is 
unpaired; and (c) -ΔG, the stability (kcal/mol) of the most stable secondary structure in which each base is unpaired. Data on 
the y-axis are obtained from the mfg computer program that simulates transcription [17].
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versus the G-to-A ratio in lung cancer; however, this has
no effect on the incidence of cancer. This key distinction
is essential to understanding the mechanisms involved.
Table 1 summarizes the relative number of mutations in
the four bases and Tables 2 and 3 show the fates of G and
C mutations in codons 210–290 of p53 for all types of
cancers (6662 total mutations, including lung), compared
to lung cancer mutations exclusively (875). The relative
percent of mutations in the four bases is remarkably sim-
ilar in lung and in all cancers, especially in view of the pre-
sumed effect of genotoxins on mutations in lung tissue
Table 3: Mutations of C to other bases in p53 codons 210–290
AGT
Total C mutations including lung 
(1875)
157 187 1531
Percent of total 8.4% 10.0% 81.6%
Lung C mutations (198) 21 31 146
Percent of lung 10.6% 15.7% 73.7%
Difference in total C mutations 
due to the presence of lung C 
mutations
+2.2% +5.7% -7.9%
All point mutations in codons 210–290 were analyzed. 
In Table 3, the ultimate fate of C mutations in all cancers due to the presence of lung cancers is shown.
Table 2: Mutations of G to other bases in p53 codons 210–290
A C T
Total G mutations including lung 
(3375)
2082 351 942
Percent of total 61.7% 10.4% 27.9%
Lung G mutations (484) 153 74 257
Percent of lung 31.6% 15.3% 53.1%
Difference in total G 
mutations due to the 
presence of lung G mutations
-30.1% +4.9% +25.2%
All point mutations in codons 210–290 were analyzed. 
Table 2 shows the ultimate fate of G mutations in all cancers due to lung cancers, with G-to-A and G-to-T mutations in bold.
Table 1: Mutations in lung compared to all cancers (including lung) in p53 codons 210–290
ACG T
Total number of all 
mutations in 240 nt (6662)
865 1875 3375 547
Percent of total 13.0% 28.1% 50.7% 8.2%
Number of lung mutations 
in 240 nt (875)
126 198 484 67
Percent of lung 14.4% 22.6% 55.3% 7.7%
Difference in total 
mutations compared to 
lung mutations
+1.4% -5.5% +4.6% -0.5%
All point mutations in codons 210–290 were analyzed. 
Table 1 shows the total number of all mutations (including lung) compared to lung mutations and the propensity of each of the four bases to 
mutate to any other base. This sequence is composed of 56 As, 66 Cs, 67 Gs, and 54 Ts. Mutations of G are shown in bold.Cancer Cell International 2006, 6:27 http://www.cancerci.com/content/6/1/27
Page 5 of 10
(page number not for citation purposes)
(Table 1). The most striking observation is that, although
the percent of G mutations in lung cancers is comparable
to the percent in all types of cancers (55.3% versus
50.7%), the base to which G most frequently mutates is
clearly different in the two data sets (Table 2). Of the total
G mutations in all cancers (including lung), 61.7% are to
A and 27.9% are to T, whereas in lung cancer mutations,
31.6% of G mutations are to A and 53.1% are to T. Thus,
the ultimate fate of mutable G bases in lung cancers
appears to be strongly influenced by the unusually potent
genotoxic agents in smoke. The observation that G-to-A
default mutations decrease to approximately the same
extent as G-to-T mutations increase suggests that these
mutations share ("compete" for) the same source of avail-
able background mutable Gs. If lung cancers were
excluded from "all cancers", it would not be possible to
depict the competition in all cancers between (default-
induced) G-to-A mutations and (genotoxin-induced) G-
to-T mutations for the (limited number of transcription-
induced) available mutable Gs. The relative percent of
mutations in the four bases is similar in lung and in all
mutations, suggesting a common regulatory mechanism
that is different from that which determines the fate of G
mutations. Note that a distinction is made between base
mutability, or the propensity of a base to mutate (deter-
mined by transcription), and the ultimate fate, or final
mutation that occurs (dependent upon the absence or
presence of a mutagen). It is the number of mutable bases
that correlate with the incidence of cancer. Having distin-
guished between the propensity of a base to mutate and
the fate or final outcome of a mutation, it should be noted
that lung mutations are characterized by a minor increase
in the number of mutable Gs (4.6%) and As (1.4%),
which could be critical to the incidence of this type of can-
cer.
Figure 2a is a visual description of the fate of G mutations
in all cancers (including lung) compared to lung cancers
(Tables 1, 2, 3), and Figure 2b depicts the "mutation flow"
or relative frequencies with which mutations of G are gen-
erated during transcription and mutate to the other three
bases, all of which result in cancer. The proposed dual
effects of genotoxins on transcription and on base damage
are also noted.
When mutations of C were analyzed (Table 3), relatively
small differences were seen in the fate of total mutable Cs
due to lung cancer C mutations. While C-to-T mutations
predominate in the data sets of both lung and all types of
Visual depictions of the frequencies and fates of G mutations due to lung cancers in p53 Figure 2
Visual depictions of the frequencies and fates of G mutations due to lung cancers in p53. (a) In lung cancer mutations com-
pared to all cancers, there is a decrease of 30.1% (orange) in G-to-A mutations, an increase of 25.2% (green) in G-to-T muta-
tions, and an increase of 4.9% (blue) in G-to-C mutations. (b) The relative number or frequency of G mutations (gray), 
resulting from transcription, compared to the relative frequencies with which these Gs mutate to the other three bases, fol-
lowing the same color scheme as in (a). The number of cancers is equal to the number of mutable Gs. The thickness of each 
arrow is proportional to percent mutation frequencies, and the dual role of genotoxins is indicated. The data are derived from 
Tables 1-3.
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cancers, proportionally fewer (7.9%) occur in the former
case.
A similar analysis (Tables 4, 5, 6) compares p53 mutations
in all cancers to colon cancers. In contrast to lung muta-
tions, in which G-to-T mutations predominate, the most
frequent G mutation in colon cancer is G-to-A. Also, while
the relative number of G mutations increase to a minor
extent in lung (4.6%), they decrease in colon cancer
(2.0%). However, a significant increase (11.9%) occurs in
Table 6: Mutations of C to other bases in p53 codons 210–290
AGT
Total C mutations including colon 
(1875)
157 187 1531
Percent of total 8.4% 10.0% 81.6%
Colon C mutations (260) 8 10 242
Percent of colon 3.1% 3.8% 93.1%
Difference in total C 
mutations due to the 
presence of colon C mutations
-5.3% -6.2% +11.5%
Analyzed as in Tables 1-3 for colon cancer. 
Table 6 shows the ultimate fate of C mutations in all types of cancers due to the presence of colon cancers.
Table 4: Mutations in colon compared to all cancers (including colon) in p53 codons 210–290
A CGT
Total number of all 
mutations in 240 nt (6662)
865 1875 3375 547
Percent of total 13.0% 28.1% 50.7% 8.2%
Number of colon 
mutations in 240 nt (651)
42 260 317 32
Percent of colon 6.4% 40.0% 48.7% 4.9%
Difference in total 
mutations compared to 
colon mutations
-6.6% +11.9% -2.0% -3.3%
Analyzed as in Tables 1-3 for colon cancer. 
Table 4 shows the total number of all mutations (including colon) compared to colon mutations and the propensity of each of the four bases to 
mutate to any other base (with mutations of both G and C in bold).
Table 5: Mutations of G to other bases in p53 codons 210–290
A C T
Total G mutations including colon 
(3375)
2082 351 942
Percent of total 61.7% 10.4% 27.9%
Colon G mutations (317) 257 19 41
Percent of colon 81.1% 6.0% 12.9%
Difference in total G 
mutations due to the 
presence of colon G 
mutations
+19.4% -4.4% -15.0%
Analyzed as in Tables 1-3 for colon cancer. 
Table 5 shows the ultimate fate of G mutations in all cancers due to colon cancers.Cancer Cell International 2006, 6:27 http://www.cancerci.com/content/6/1/27
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the relative number of mutable Cs, suggesting an associa-
tion with the development of colon cancer. Moreover, the
fate of mutable Gs and Cs is in striking contrast to that
seen in lung cancer mutations. The fate of mutable Cs is
primarily to Ts, while there are relatively more G-to-A
default mutations compared to G-to-T mutations. How-
ever, as all of these mutation fates are associated with can-
cer, they do not alter the frequency with which it occurs.
The increased availability of background mutable Cs may
be critical to the increased frequency of colon cancer.
These results also suggest that a different mutagenic mech-
anism is operative in colon versus lung cancer.
Results from the analyses of lung cancer mutations in p53
codons 210–290 (Tables 1, 2, 3) prompted a similar
examination of 15 hypermutable bases in codons 213,
220, 245, 248, 249, 273, and 282 (the first two positions
of all codons plus the third position of codon 249)
(Tables 7, 8, 9). Note that the evolution of hypermutable
bases has resulted in twice as many mutable G sites as C
sites in this more selective hypermutable subset, and that
there is a clear increase (10.7%) in the number of G muta-
tions, again suggesting a causal relationship with the inci-
dence of lung cancer. As in Table 2, compensatory shifts
are seen in the percent of Gs that mutate to A versus T in
lung cancer mutations compared to total mutations
(Table 8). The data show a 34.5% increase in G-to-T and
a 6.6% increase in G-to-C mutations in lung cancers,
accompanied by a 41.1% decrease in G mutations to A.
This is consistent with a shared source of mutable Gs, as
seen in Table 2. Partitioning the fates of mutable Cs to the
other bases also occurs (Table 9), but the effects are
minor.
In p53, an excellent correlation is seen between observed
and predicted mutation frequency for the non-transcribed
strand (Fig. 1), while no correlation exists for the tran-
scribed strand. Thus, while a C-to-A transversion on the
transcribed strand could occur to produce a T in the non-
transcribed strand via mismatch repair, this mechanism
probably makes a small contribution to the results of our
analyses.
Codons 248 and 273 play a critical role in DNA binding,
in addition to having the highest predicted and observed
mutation frequencies in the p53 mutation database [17].
These codons were therefore chosen to further refine our
analyses of the hypermutable bases. The results are seen in
Tables 10, 11, 12, and a comparison with Tables 7, 8, 9
indicates that the characteristics of these two codons are
typical of those seen for the other hypermutable lung can-
cer analyses.
Conclusion
These studies indicate that genotoxin-induced G-to-T base
damage to p53 is not correlated with the incidence of lung
cancer, which must therefore be due to a different mecha-
nism. We propose that mild base damage by genotoxins
provokes the stress response during which p53 promoter
elements are activated, leading to transcription, hypermu-
tation, the loss of p53 regulatory functions, and ultimately
to cancer. A variety of experimental evidence supports this
mechanism: (a) genotoxins induce upregulation of p53
transcription [9,21-24]; (b) persistently upregulated p53
expression is associated with the accumulation of p53
mutations and tumorigenesis [19,20]; (c) intrinsically
mutable unpaired bases in secondary structures are
formed during transcription [26,29,30]; and (d) an excel-
lent correlation exists (Fig. 1) between observed mutation
frequencies in p53  and base mutability predicted by a
model of transcription-induced mutagenesis [17].
Although these experimental lines of evidence do not
address the possibility of a dual role for carcinogens in
mutagenesis, the insights obtained from Tables 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12 provide strong support for the exist-
ence of two different, as well as independent mechanisms
induced by genotoxins. The newly discovered relation-
ships described above suggest that the same mechanism
regulates the number of mutable bases in lung cancer as
in all cancers, and that this mechanism (transcription) dif-
fers from that regulating the fate of the mutable bases, e.g.,
the number of available mutable Gs that mutate to T ver-
sus the number that mutate to A. Further, the data
describe the two independent roles of genotoxins: first,
they upregulate p53 transcription and increase the availa-
bility of mutable bases, which determines the incidence of
cancer, and second, they inflict base damage, e.g., increase
the ratio of G-to-T versus G-to-A mutations, which has no
affect on the frequency of cancer. These analyses are con-
sistent with the conclusion that transcription-exposed
mutable bases determine the incidence of cancer, which is
also the conclusion of an independent analysis of hyper-
mutable bases using the computer algorithm, mfg (Fig. 1).
The development of cancer clearly involves a complex
series of mutagenic and selective events. It now appears
that these events may include the participation of tran-
scription-driven secondary structures and intrinsically
mutable bases encoded within the p53 gene.
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Table 9: Mutations of C to other bases in fifteen hypermutable bases of p53
AGT
Total C mutations including lung 
(1195)
17 49 1129
Percent of total 1.4% 4.1% 94.5%
Lung C mutations (107) 3 9 95
Percent of lung 2.8% 8.4% 88.8%
Difference in total C mutations 
due to the presence of lung C 
mutations
+1.4% +4.3% -5.7%
These hypermutable bases consist of the first two positions of codons 213, 220, 245, 248, 273, and 282 and all positions in codon 249. 
The composition of the bases analyzed is 2 As, 4 Cs, 8Gs, and 1T. Table 9 shows the ultimate fate of C mutations in all cancers due to the 
presence of lung cancers.
Table 7: Mutations in lung compared to all cancers in fifteen hypermutable bases of p53
ACG T
Total number of all 
mutations in 15 nt (3292)
225 1195 1857 15
Percent of total 6.8% 36.3% 56.4% 0.5%
Number of lung mutations 
in 15 nt (407)
26 107 273 1
Percent of lung 6.4% 26.3% 67.1% 0.2%
Difference in total 
mutations compared to 
lung mutations
-0.4% -10.0% +10.7% -0.3%
These hypermutable bases consist of the first two positions of codons 213, 220, 245, 248, 273, and 282 and all positions in codon 249. 
The composition of the bases analyzed is 2 As, 4 Cs, 8Gs, and 1T. Table 7 shows the total number of all mutations (including lung) compared to 
lung mutations and the propensity of these mutable bases to mutate to any other base (with mutations of G in bold).
Table 8: Mutations of G to other bases in fifteen hypermutable bases of p53
A C T
Total G mutations including lung 
(1857)
1214 107 536
Percent of total 65.3% 5.8% 28.9%
Lung G mutations (273) 66 34 173
Percent of lung 24.2% 12.4% 63.4%
Difference in total G 
mutations due to the 
presence of lung G mutations
-41.1% +6.6% +34.5%
These hypermutable bases consist of the first two positions of codons 213, 220, 245, 248, 273, and 282 and all positions in codon 249. 
The composition of the bases analyzed is 2 As, 4 Cs, 8Gs, and 1T. Table 8 shows the ultimate fate of G mutations in all cancers due to lung 
mutations (with G-to-A and G-to-T in bold).Cancer Cell International 2006, 6:27 http://www.cancerci.com/content/6/1/27
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Table 12: Mutations of C to other bases in hypermutable codons 248 and 273
AGT
Total C mutations including lung 
(728)
11 21 696
Percent of total 1.5% 2.9% 95.6%
Lung mutations (63) 3 2 58
Percent of lung 4.8% 3.2% 92.1%
Difference in total C mutations 
due to the presence of lung C 
mutations
+3.3% +0.3% -3.5%
These hypermutable bases consist of the first two positions of codons 248 and 273. 
The composition of the bases analyzed is 2 Cs and 2Gs. Table 12 shows the ultimate fate of C mutations in all cancers due to the presence of lung 
cancers.
Table 10: Mutations in lung compared to all cancers in hypermutable codons 248 and 273
ACG T
Total number of mutations 
in 4 nt (1775)
07 2 8 1047 0
Percent of total 0 41.0% 59.0% 0
Number of lung mutations 
in 4 nt (187)
06 3 124 0
Percent of lung 0 33.7% 66.3% 0
Difference in total 
mutations compared to 
lung mutations
0- 7 . 3 % +7.3% 0
These hypermutable bases consist of the first two positions of codons 248 and 273. 
The composition of the bases analyzed is 2 Cs and 2Gs. Table 10 shows the total number of mutations (including lung) compared to lung 
mutations and the propensity of these mutable bases to mutate to any other base (with total mutations of G in bold).
Table 11: Mutations of G to other bases in hypermutable codons 248 and 273
A C T
Total G mutations including lung 
(1047)
863 31 153
Percent of total 82.4% 3.0% 14.6%
Lung G mutations (124) 46 9 69
Percent of lung 37.1% 7.3% 55.6%
Difference in total G 
mutations due to the 
presence of lung mutations
-45.3% +4.3% +41.0%
These hypermutable bases consist of the first two positions of codons 248 and 273. 
The composition of the bases analyzed is 2 Cs and 2Gs. Table 11 shows the ultimate fate of G mutations in all cancers due to lung mutations (with 
G-to-A and G-to-T in bold).Publish with BioMed Central    and   every 
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